MeSH tree: D12.776.124.486.485.114.224
First-line regimens with endocrine therapy (ET) may be associated with benefits among patients with human epidermal growth factor receptor 2-positive (ERBB2-positive [formerly HER2-positive]) metastatic breast cancer (MBC), ...
Dec 20, 2022
0
31
In the competition between brand name pharmaceuticals and their generic counterparts, drug companies use patent gamesmanship to their advantage, one West Virginia University patent expert said.
Dec 19, 2022
0
47
For many parents, respiratory syncytial virus—or RSV—which has been causing record numbers of hospitalizations of children during the fall of 2022, may sound like a relatively new and unheard-of threat. But in fact, RSV is ...
Dec 16, 2022
0
21
New research has confirmed a strong link between four genetic mutations and progressive multifocal leukoencephalopathy (PML), a rare but often fatal brain infection that can be triggered by dozens of FDA-approved drugs.
Dec 14, 2022
1
95
A new research paper titled "Combined epigenetic and immunotherapy for blastic and classical mantle cell lymphoma" has been published in Oncotarget.
Dec 13, 2022
0
44
Researchers at Lund University in Sweden have discovered an antibody with the potential to protect against Strep A infection, as well as a rare form of antibody binding, that leads to an effective immune response against ...
Dec 12, 2022
0
69
The Food and Drug Administration (FDA) recently approved a medication that can delay the onset of type 1 diabetes. This marks the first treatment to change the course of this autoimmune disease since the discovery of insulin ...
Dec 9, 2022
0
88
A patient's own immune cells, multiplied into an army of billions of immune cells in a lab, can be used as a living medicine against metastatic melanoma, an aggressive form of skin cancer, as the TIL trial has shown. The ...
Dec 8, 2022
0
61
Compared with capecitabine-based regimens, trastuzumab deruxtecan (T-DXd) led to higher response rates and longer survival in the third-line setting for patients with HER2-positive metastatic breast cancer previously treated ...
Dec 7, 2022
0
31
Second-line treatment with trastuzumab deruxtecan (T-DXd) led to significantly longer overall survival compared with trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer, according to updated ...
Dec 7, 2022
0
23
